tiprankstipranks
Fortress Biotech Inc (FBIO)
NASDAQ:FBIO
US Market
FBIO
Fortress Biotech
RESEARCH TOOLSreports
Want to see FBIO full AI Analyst Report?

Fortress Biotech (FBIO) Earnings Dates, Call Summary & Reports

1,586 Followers

Earnings Data

Report Date
Aug 17, 2026
TBA (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
-0.2
Last Year’s EPS
0.45
Same Quarter Last Year
Analyst Consensus
Moderate Buy
Based on 1 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 14, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth driven by the successful launch of EMROSI, improved EBITDA, and expanding prescriber base. However, challenges remain with the decline in legacy product revenues and delays in health plan formulary adoption for EMROSI. Despite these issues, the company is optimistic about EMROSI's potential and future revenue growth.
Company Guidance
During Journey Medical's third-quarter 2025 earnings call, the company provided guidance highlighting a strong performance and optimistic outlook, driven by the successful launch of EMROSI, their oral treatment for rosacea. The company reported a 21% year-over-year revenue growth, with EMROSI contributing $4.9 million in Q3, marking a 75% increase from Q2. Total revenues reached $17.6 million, supported by a gross margin improvement from 63.5% in Q1 to 67.4% in Q3. The company observed a 146% increase in EMROSI prescriptions, totaling 18,198 in Q3, compared to 7,394 in Q2. Operating expenses increased by 9%, while SG&A expenses rose by 6% year-over-year, reflecting activities tied to the EMROSI launch. Non-GAAP adjusted EBITDA improved to $1.7 million, with the expectation of becoming sustainably EBITDA positive in Q4. Journey Medical also mentioned their payer strategy progress, with over 100 million of the 187 million commercial lives having access to EMROSI. The company anticipates peak annual net sales of over $200 million in the U.S. and over $300 million globally for EMROSI.
Significant Revenue Growth
Journey Medical reported a 21% year-over-year revenue growth for Q3 2025, reaching $17.6 million compared to $14.9 million in Q3 2024.
EMROSI's Strong Performance
EMROSI contributed $4.9 million to the top line in Q3, an increase of 75% from Q2, with total prescription growth of approximately 146%.
Positive EBITDA Trends
Non-GAAP EBITDA improved by $500,000 year-over-year, with positive adjusted EBITDA of $1.7 million for Q3 2025, compared to $300,000 in Q3 2024.
Increased Prescriber Base for EMROSI
The number of unique EMROSI prescribers increased by approximately 50% to over 2,700, indicating a strong adoption among dermatologists.
Market Access Achievements
Over 100 million of the 187 million commercial lives currently have access to EMROSI, with plans to contract with the remaining major GPO early next year.

Fortress Biotech (FBIO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

FBIO Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 17, 2026
2026 (Q2)
-0.20 / -
0.45―――
May 14, 2026
2026 (Q1)
- / 2.82
-0.48687.50% (+3.30)―
Mar 31, 2026
2025 (Q4)
-0.22 / 2.82
-0.48687.50% (+3.30)――
Nov 14, 2025
2025 (Q3)
-0.42 / 0.11
-0.76114.47% (+0.87)―
Aug 14, 2025
2025 (Q2)
-0.36 / 0.45
-0.73161.64% (+1.18)――
May 15, 2025
2025 (Q1)
- / -
-1.03―――
Mar 31, 2025
2024 (Q4)
-0.49 / -0.48
-1.0353.40% (+0.55)――
Nov 14, 2024
2024 (Q3)
-0.59 / -0.76
-0.9419.15% (+0.18)――
Aug 13, 2024
2024 (Q2)
-1.22 / -0.73
-3.679.72% (+2.87)――
May 08, 2024
2024 (Q1)
-1.73 / -1.03
-3.1567.30% (+2.12)――
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

FBIO Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 14, 2026
$2.30$2.41+4.78%
Mar 31, 2026
$2.79$2.47-11.47%
Nov 14, 2025
$2.49$2.62+5.22%
Aug 14, 2025
$1.96$2.12+8.16%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Fortress Biotech Inc (FBIO) report earnings?
Fortress Biotech Inc (FBIO) is schdueled to report earning on Aug 17, 2026, TBA (Confirmed).
    What is Fortress Biotech Inc (FBIO) earnings time?
    Fortress Biotech Inc (FBIO) earnings time is at Aug 17, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is FBIO EPS forecast?
          FBIO EPS forecast for the fiscal quarter 2026 (Q2) is -0.2.